Hepatocellular Carcinoma – Pipeline Review, H1 2012

Introduction

Global Markets Direct’s, 'Hepatocellular Carcinoma - Pipeline Review, H1 2012', provides an overview of the Hepatocellular Carcinoma therapeutic pipeline. This report provides information on the therapeutic development for Hepatocellular Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma. 'Hepatocellular Carcinoma - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hepatocellular Carcinoma.
- A review of the Hepatocellular Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hepatocellular Carcinoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Highlights

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Hepatocellular Carcinoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
[Studien Infos ausblenden]

Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Hepatocellular Carcinoma Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Hepatocellular Carcinoma 13
Hepatocellular Carcinoma Therapeutics under Development by Companies 15
Hepatocellular Carcinoma Therapeutics under Investigation by Universities/Institutes 20
Late Stage Products 28
Comparative Analysis 28
Mid Clinical Stage Products 29
Comparative Analysis 29
Early Clinical Stage Products 30
Comparative Analysis 30
Discovery and Pre-Clinical Stage Products 31
Comparative Analysis 31
Hepatocellular Carcinoma Therapeutics – Products under Development by Companies 32
Hepatocellular Carcinoma Therapeutics – Products under Investigation by Universities/Institutes 38
Companies Involved in Hepatocellular Carcinoma Therapeutics Development 49
Bristol-Myers Squibb Company 49
Boehringer Ingelheim GmbH 50
F. Hoffmann-La Roche Ltd. 51
Celsion Corporation 52
Abbott Laboratories 53
Biogen Idec Inc. 54
Amgen Inc. 55
Sanofi-Aventis 56
AstraZeneca PLC 57
Eli Lilly and Company 58
GlaxoSmithKline plc 59
Daiichi Sankyo Company, Ltd 60
Light Sciences Oncology, Inc. 61
ZIOPHARM Oncology, Inc. 62
Novartis AG 63
ImClone Systems Incorporated 64
Chugai Pharmaceutical Co. Ltd 65
Eisai Co., Ltd. 66
Human Genome Sciences, Inc. 67
OSI Pharmaceuticals, Inc. 68
Pfizer Inc. 69
Taiho Pharmaceutical Co., Ltd. 70
Hadasit Medical Research Services & Development Ltd 71
Exelixis, Inc. 72
Bayer AG 73
4SC AG 74
Can-Fite BioPharma Ltd. 75
Ligand Pharmaceuticals Incorporated 76
NexMed, Inc. 77
Novogen Limited 78
Cleveland BioLabs, Inc. 79
Peregrine Pharmaceuticals, Inc. 80
ARQULE, INC 81
Transgene SA 82
Sirtex Medical Limited 83
Progen Pharmaceuticals Limited 84
Innocell Corporation 85
Jiangsu Hengrui Medicine Co., Ltd. 86
Provectus Pharmaceuticals, Inc. 87
Synta Pharmaceuticals Corp. 88
BioAlliance Pharma SA 89
Raptor Pharmaceuticals Corp. 90
RXi Pharmaceuticals Corporation 91
ERYtech Pharma 92
Provecs Medical GmbH 93
TMRC Co., Ltd. 94
Pharmascience Inc. 95
Mondobiotech Holding AG 96
Celecure AS 97
Jennerex Biotherapeutics, Inc. 98
AndroScience Corporation 99
MolMed S.p.A. 100
Mirna Therapeutics, Inc. 101
CureTech Ltd. 102
TRACON Pharmaceuticals, Inc. 103
Regulus Therapeutics Inc. 104
KAEL-GemVax 105
Therapure Biopharma Inc. 106
VectorLogics, Inc. 107
Polaris Group 108
Hepatocellular Carcinoma – Therapeutics Assessment 109
Assessment by Monotherapy Products 109
Assessment by Combination Products 110
Assessment by Route of Administration 111
Assessment by Molecule Type 114
Drug Profiles 117
BMS-582664 - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
ABT-869 - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
Livatag - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
Afinitor - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
IMC-1121B - Drug Profile 125
Product Description 125
Mechanism of Action 125
R&D Progress 125
Thermodox - Drug Profile 127
Product Description 127
Mechanism of Action 127
R&D Progress 127
Muparfostat - Drug Profile 129
Product Description 129
Mechanism of Action 129
R&D Progress 129
TSU68 - Drug Profile 131
Product Description 131
Mechanism of Action 131
R&D Progress 131
Aptocine - Drug Profile 132
Product Description 132
Mechanism of Action 132
R&D Progress 132
PrevOnco + Doxorubicin - Drug Profile 134
Product Description 134
Mechanism of Action 134
R&D Progress 134
Eloxatin + 5-Fluorouracil + Leucovorin - Drug Profile 135
Product Description 135
Mechanism of Action 135
R&D Progress 135
Xeloda - Drug Profile 137
Product Description 137
Mechanism of Action 137
R&D Progress 137
Sorafenib + Transarterial Chemoembolisation - Drug Profile 138
Product Description 138
Mechanism of Action 138
R&D Progress 138
ADI-PEG 20 - Drug Profile 139
Product Description 139
Mechanism of Action 139
R&D Progress 139
PrevOnco - Drug Profile 141
Product Description 141
Mechanism of Action 141
R&D Progress 141
Eloxatin + 5-FU + Leucovorin - Drug Profile 142
Product Description 142
Mechanism of Action 142
R&D Progress 142
Nexavar + Tarceva - Drug Profile 144
Product Description 144
Mechanism of Action 144
R&D Progress 144
Sirolimus - Drug Profile 145
Product Description 145
Mechanism of Action 145
R&D Progress 145
Thymopentin - Drug Profile 146
Product Description 146
Mechanism of Action 146
R&D Progress 146
Doxorubicin + Sorafenib - Drug Profile 147
Product Description 147
Mechanism of Action 147
R&D Progress 147
Sirolimus - Drug Profile 149
Product Description 149
Mechanism of Action 149
R&D Progress 149
Cisplatin + Doxorubicin + Mitomycin C + Sorafenib - Drug Profile 150
Product Description 150
Mechanism of Action 150
R&D Progress 150
Immuncell-LC - Drug Profile 152
Product Description 152
Mechanism of Action 152
R&D Progress 152
Sirolimus - Drug Profile 153
Product Description 153
Mechanism of Action 153
R&D Progress 153
Sorafenib - Drug Profile 154
Product Description 154
Mechanism of Action 154
R&D Progress 154
Tarceva - Drug Profile 155
Product Description 155
Mechanism of Action 155
R&D Progress 155
cisplatin - Drug Profile 157
Product Description 157
Mechanism of Action 157
R&D Progress 157
Thalidomide + TACE - Drug Profile 158
Product Description 158
Mechanism of Action 158
R&D Progress 158
Octreotide-LAR + Lanreotide Autogel - Drug Profile 159
Product Description 159
Mechanism of Action 159
R&D Progress 159
Sorafenib + Pravastatin - Drug Profile 161
Product Description 161
Mechanism of Action 161
R&D Progress 161
Adefovir Dipivoxil + Lamivudine - Drug Profile 162
Product Description 162
Mechanism of Action 162
R&D Progress 162
Sorafenib + Cisplatin + Fluorouracil - Drug Profile 163
Product Description 163
Mechanism of Action 163
R&D Progress 163
FOLFOX6 + Sir-Spheres Microspheres + Avastin - Drug Profile 165
Product Description 165
Mechanism of Action 165
R&D Progress 166
Eloxatin + Capecitabine + Sorafenib - Drug Profile 167
Product Description 167
Mechanism of Action 167
R&D Progress 167
Sunitinib + Chemoembolization - Drug Profile 169
Product Description 169
Mechanism of Action 169
R&D Progress 169
S-1 - Drug Profile 170
Product Description 170
Mechanism of Action 170
R&D Progress 170
Hepatocellular Carcinoma Therapeutics – Drug Profile Updates 171
Hepatocellular Carcinoma Therapeutics – Discontinued Products 183
Hepatocellular Carcinoma Therapeutics - Dormant Products 185
Hepatocellular Carcinoma – Product Development Milestones 191
Featured News & Press Releases 191
Jan 03, 2012: Can-Fite BioPharma Announces Successful Results Of Phase I/II Liver Cancer Study With CF102 191
Dec 22, 2011: Bristol-Myers Squibb Completes BRISK-PS Study Of Brivanib In Hepatocellular Carcinoma 192
Dec 19, 2011: Celsion Completes Consultative Review Process With EMA For Phase III HEAT Study Of ThermoDox In Primary Liver Cancer 192
Dec 07, 2011: 4SC Obtains Key Patent For Resminostat In Japan 193
Dec 06, 2011: 4SC To Present Clinical Development Program With Resminostat At World Epigenetics Summit 194
Nov 28, 2011: Celsion Announces Unanimous Recommendation By Independent Data Monitoring Committee To Continue And Complete Phase III HEAT Study Of ThermoDox In Primary Liver Cancer 194
Nov 04, 2011: Jennerex Announces First Patient Randomized In Phase IIb Clinical Trial Of JX-594 In Liver Cancer 195
Sep 13, 2011: Bayer To Present New Data On Regorafenib At 2011 ECCO-ESMO Congress 196
Appendix 199
Methodology 199
Coverage 199
Secondary Research 199
Primary Research 199
Expert Panel Validation 200
Contact Us 200
Disclaimer 200
[Inhaltsverzeichnis ausblenden]

List of Tables
Number of Products Under Development for Hepatocellular Carcinoma, H1 2012 13
Products under Development for Hepatocellular Carcinoma – Comparative Analysis, H1 2012 14
Number of Products under Development by Companies, H1 2012 16
Number of Products under Development by Companies, H1 2012 (Contd..1) 17
Number of Products under Development by Companies, H1 2012 (Contd..2) 18
Number of Products under Development by Companies, H1 2012 (Contd..3) 19
Number of Products under Investigation by Universities/Institutes, H1 2012 21
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 22
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 23
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 24
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 25
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 26
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 27
Comparative Analysis by Late Stage Development, H1 2012 28
Comparative Analysis by Mid Clinical Stage Development, H1 2012 29
Comparative Analysis by Early Clinical Stage Development, H1 2012 30
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 31
Products under Development by Companies, H1 2012 32
Products under Development by Companies, H1 2012 (Contd..1) 33
Products under Development by Companies, H1 2012 (Contd..2) 34
Products under Development by Companies, H1 2012 (Contd..3) 35
Products under Development by Companies, H1 2012 (Contd..4) 36
Products under Development by Companies, H1 2012 (Contd..5) 37
Products under Investigation by Universities/Institutes, H1 2012 38
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 39
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 40
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 41
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 42
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 43
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 44
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 45
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 46
Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 47
Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 48
Bristol-Myers Squibb Company, H1 2012 49
Boehringer Ingelheim GmbH, H1 2012 50
F. Hoffmann-La Roche Ltd., H1 2012 51
Celsion Corporation, H1 2012 52
Abbott Laboratories, H1 2012 53
Biogen Idec Inc., H1 2012 54
Amgen Inc., H1 2012 55
Sanofi-Aventis, H1 2012 56
AstraZeneca PLC, H1 2012 57
Eli Lilly and Company, H1 2012 58
GlaxoSmithKline plc, H1 2012 59
Daiichi Sankyo Company, Ltd, H1 2012 60
Light Sciences Oncology, Inc., H1 2012 61
ZIOPHARM Oncology, Inc., H1 2012 62
Novartis AG, H1 2012 63
ImClone Systems Incorporated, H1 2012 64
Chugai Pharmaceutical Co. Ltd, H1 2012 65
Eisai Co., Ltd., H1 2012 66
Human Genome Sciences, Inc., H1 2012 67
OSI Pharmaceuticals, Inc., H1 2012 68
Pfizer Inc., H1 2012 69
Taiho Pharmaceutical Co., Ltd., H1 2012 70
Hadasit Medical Research Services & Development Ltd, H1 2012 71
Exelixis, Inc., H1 2012 72
Bayer AG, H1 2012 73
4SC AG, H1 2012 74
Can-Fite BioPharma Ltd., H1 2012 75
Ligand Pharmaceuticals Incorporated, H1 2012 76
NexMed, Inc., H1 2012 77
Novogen Limited, H1 2012 78
Cleveland BioLabs, Inc., H1 2012 79
Peregrine Pharmaceuticals, Inc., H1 2012 80
ARQULE, INC, H1 2012 81
Transgene SA, H1 2012 82
Sirtex Medical Limited, H1 2012 83
Progen Pharmaceuticals Limited, H1 2012 84
Innocell Corporation, H1 2012 85
Jiangsu Hengrui Medicine Co., Ltd., H1 2012 86
Provectus Pharmaceuticals, Inc., H1 2012 87
Synta Pharmaceuticals Corp., H1 2012 88
BioAlliance Pharma SA, H1 2012 89
Raptor Pharmaceuticals Corp., H1 2012 90
RXi Pharmaceuticals Corporation, H1 2012 91
ERYtech Pharma, H1 2012 92
Provecs Medical GmbH, H1 2012 93
TMRC Co., Ltd., H1 2012 94
Pharmascience Inc., H1 2012 95
Mondobiotech Holding AG, H1 2012 96
Celecure AS, H1 2012 97
Jennerex Biotherapeutics, Inc., H1 2012 98
AndroScience Corporation, H1 2012 99
MolMed S.p.A., H1 2012 100
Mirna Therapeutics, Inc., H1 2012 101
CureTech Ltd., H1 2012 102
TRACON Pharmaceuticals, Inc., H1 2012 103
Regulus Therapeutics Inc., H1 2012 104
KAEL-GemVax, H1 2012 105
Therapure Biopharma Inc., H1 2012 106
VectorLogics, Inc., H1 2012 107
Polaris Group, H1 2012 108
Assessment by Monotherapy Products, H1 2012 109
Assessment by Combination Products, H1 2012 110
Assessment by Stage and Route of Administration, H1 2012 113
Assessment by Molecule Type, H1 2012 116
Hepatocellular Carcinoma Therapeutics – Drug Profile Updates 171
Hepatocellular Carcinoma Therapeutics – Discontinued Products 183
Hepatocellular Carcinoma Therapeutics – Discontinued Products (Contd..1) 184
Hepatocellular Carcinoma Therapeutics – Dormant Products 185
Hepatocellular Carcinoma Therapeutics – Dormant Products (Contd..1) 186
Hepatocellular Carcinoma Therapeutics – Dormant Products (Contd..2) 187
Hepatocellular Carcinoma Therapeutics – Dormant Products (Contd..3) 188
Hepatocellular Carcinoma Therapeutics – Dormant Products (Contd..4) 189
Hepatocellular Carcinoma Therapeutics – Dormant Products (Contd..5) 190
List of Figures
Number of Products under Development for Hepatocellular Carcinoma, H1 2012 13
Products under Development for Hepatocellular Carcinoma – Comparative Analysis, H1 2012 14
Products under Development by Companies, H1 2012 15
Products under Investigation by Universities/Institutes, H1 2012 20
Late Stage Products, H1 2012 28
Mid Clinical Stage Products, H1 2012 29
Early Clinical Stage Products, H1 2012 30
Discovery and Pre-Clinical Stage Products, H1 2012 31
Assessment by Monotherapy Products, H1 2012 109
Assessment by Combination Products, H1 2012 110
Assessment by Route of Administration, H1 2012 111
Assessment by Stage and Route of Administration, H1 2012 112
Assessment by Molecule Type, H1 2012 114
Assessment by Stage and Molecule Type, H1 2012 115
[Tabellenverzeichnis ausblenden]